Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - RegenoCELL Therapeutics, Inc. | Financial_Report.xls |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT ONE TO FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2011
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission File Number: 000-50639
REGENOCELL THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Florida
|
22-3880440
|
|
(State or other jurisdiction of incorporation
|
(I.R.S. Employer Identification No.)
|
|
or organization)
|
2 Briar Lane
Natick, Massachusetts 01760
(Address of Principal Executive Offices)
(508) 647-4065
(Registrant's telephone number, including area code)
Check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Yes x No o
|
Large Accelerated filer o
|
Accelerated filer o
|
|
Non-accelerated filer (Do not check if a smaller reporting company) o
|
Smaller reporting company x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of the registrant's common stock, par value $0.0001 per share, outstanding as of the latest practical date. 81,962,500 shares of common stock outstanding as of August 15, 2011.
REGENOCELL THERAPEUTICS, INC.
Amendment One to Quarterly Report on Form 10-Q
For the Quarterly Period Ended June 30, 2011
This Amendment One to Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011 is being filed to include the Company’s first Interactive Data File as Exhibit 101.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
REGENOCELL THERAPEUTICS, INC.
|
|||
|
Dated: September 1 , 2011
|
By:
|
/s/ James F. Mongiardo | |
|
James F. Mongiardo
|
|||
|
Principal Executive Officer,
President, Principal Financial Officer,
Principal Accounting Officer, and
Director
|
|||
EXHIBIT INDEX
Exhibit
|
Number
|
Description of Document
|
|
101
|
The following materials from RegenoCELL Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.
|